European asymmetries: A comparative analysis of German and UK biotechnology clusters

Philip Cooke

Science and Public Policy, 2007, vol. 34, issue 7, 454-474

Abstract: This paper updates to 2006 material first gathered in the late 1990s. Though Germany has about the same number of firms as the UK its biotechnology economy is far weaker, with many small firms employing few people, relatively low venture capital investment and little interest being shown by pharmaceuticals companies in licensing intellectual property. The reverse is the case in the UK even though the investor euphoria at the time of the first comparative study has not returned. A new policy of ‘entrepreneurship outsourcing’ has become visible in the UK as venture capital perceives a better business climate for biotechnology entrepreneurship in the USA. Recent developments of this kind may add to debilitating European problems, loosening more proximate links within national and regional innovation systems widely perceived as highly important elements in biotechnology cluster performance. Copyright , Beech Tree Publishing.

Date: 2007
References: Add references at CitEc
Citations: View citations in EconPapers (11)

Downloads: (external link)
http://hdl.handle.net/10.3152/030234207X251425 (application/pdf)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:oup:scippl:v:34:y:2007:i:7:p:454-474

Access Statistics for this article

Science and Public Policy is currently edited by Nicoletta Corrocher, Jeong-Dong Lee, Mireille Matt and Nicholas Vonortas

More articles in Science and Public Policy from Oxford University Press
Bibliographic data for series maintained by Oxford University Press ().